| 000 | 01893 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250513185547.0 | ||
| 264 | 0 | _c19990824 | |
| 008 | 199908s 0 0 eng d | ||
| 022 | _a0020-7136 | ||
| 024 | 7 |
_a10.1002/(sici)1097-0215(19990820)84:4<354::aid-ijc4>3.0.co;2-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMiles, D W | |
| 245 | 0 | 0 |
_aEffect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. _h[electronic resource] |
| 260 |
_bInternational journal of cancer _cAug 1999 |
||
| 300 |
_a354-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBreast Neoplasms _xmortality |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluorouracil _xadministration & dosage |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLymph Node Excision |
| 650 | 0 | 4 | _aLymphatic Metastasis |
| 650 | 0 | 4 | _aMastectomy |
| 650 | 0 | 4 | _aMenopause |
| 650 | 0 | 4 |
_aMethotrexate _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xanalysis |
| 650 | 0 | 4 |
_aReceptors, Estrogen _xanalysis |
| 650 | 0 | 4 | _aRegression Analysis |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aHarris, W H | |
| 700 | 1 | _aGillett, C E | |
| 700 | 1 | _aSmith, P | |
| 700 | 1 | _aBarnes, D M | |
| 773 | 0 |
_tInternational journal of cancer _gvol. 84 _gno. 4 _gp. 354-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/(sici)1097-0215(19990820)84:4<354::aid-ijc4>3.0.co;2-6 _zAvailable from publisher's website |
| 999 |
_c10362275 _d10362275 |
||